#Atripla

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Such generic drugs could save nations huge sums in the coming years.

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.

Gilead Sciences’ fixed-dose combination pill of Sovaldi (sofosbuvir) and the investigational ledipasvir, likely to receive FDA approval on Oct...

The Sovaldi/ledipasvir combination pill to treat hepatitis C does not have a clinically significant impact on five common HIV antiretrovirals.

Viread (tenofovir) and Epivir (lamivudine) lower the risk of infection with hepatitis B among HIV-positive gay men who havenâ€™t been vac...

Hepatitis B virus infection raises the risk of death by 75 percent for those who are also coinfected with hepatitis C virus and HIV.

Important preliminary recommendations involving the use of hepatitis C protease inhibitors among people living with HIV are provided by U.S. D...

The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...

The odds of curing hep C are now better than ever.

People coinfected with both HIV and HBV are much more likely to develop mild kidney problems after starting tenofovir

A new study has found that the overall rate of kidney dysfunction was only 3 percent in a group of HIV-positive military personnel, but severa...

Tobacco and alcohol interact negatively with efavirenz (found in Sustiva and Atripla) in people who are genetically predisposed to clear efa...